Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pifusertib (TAS-117)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

AKT inhibitor

Related drugs:

‹

›

PIK3CA E545K	Ovarian Cancer	PIK3CA E545K	Ovarian Cancer	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3
PIK3CA H1047R	Breast Cancer	PIK3CA H1047R	Breast Cancer	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3
AKT1 E17K	Breast Cancer	AKT1 E17K	Breast Cancer	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3	TAS-117 Sensitive: C3 – Early Trials TAS-117 Sensitive : C3
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	TAS-117 Sensitive: C4 – Case Studies TAS-117 Sensitive : C4	TAS-117 Sensitive: C4 – Case Studies TAS-117 Sensitive : C4
FGFR2 N549K	Endometrial Cancer	FGFR2 N549K	Endometrial Cancer	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D
FGFR1 amplification	Small Cell Lung Cancer	FGFR1 amplification	Small Cell Lung Cancer	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D	futibatinib + TAS-117 Sensitive: D – Preclinical futibatinib + TAS-117 Sensitive : D
EZH2 deletion	Multiple Myeloma	EZH2 deletion	Multiple Myeloma	TAS-117 Sensitive: D – Preclinical TAS-117 Sensitive : D	TAS-117 Sensitive: D – Preclinical TAS-117 Sensitive : D